ScisGo® HLA v6 Kits

Phased 3-field HLA typing in a single assay using proven Scisco Genetics technology.

Cat. No. HLA-24S-v6

Highlights

  • Class I HLA -A, -B, -C exons 1-7
  • Class II HLA-DRB1345, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 exons 1-4
  • Phased 3-field typing across all loci
  • All known null alleles detected
  • Simple, PCR-only protocol
  • No robotics
  • Total DNA input as low as 10 ng
  • DNA from a variety of sources including saliva, buccal swabs, and dried blood spots
  • DNA to Data in 30 hours

Overview

The human leukocyte antigens (HLA) are intimately involved in the innate and adaptive immune responses, communicating normal and abnormal cellular status to surveying immune cells. These highly polymorphic genes can greatly affect the outcome of hematopoietic cell and solid organ transplantation, in addition to their consequential roles in infectious disease, autoimmunity, and cancer.

Our NGS solution for HLA class I and II typing is carried out via multiplex PCR of HLA specific amplicons. Exon and flanking intron sequences from the HLA genes are amplified in 4 reactions, simultaneously tagged with index sequences (to distinguish samples), pooled, and sequenced. Data can be stored, analyzed on the cloud, and visualized on your desktop computer using our GeMS (Genetics Management System) analysis software.

ScisGo® Chimerism Multi Donor Kits

Chimerism testing of patients after HSCT to determine recipient/donor origin of nucleated hematopoietic cells.

Cat. No. CHIM-24S-MD

Highlights

  • All chromosomes sampled
  • Next Generation Sensitivity, down to 0.1%
  • Simple, PCR-only protocol
  • Total DNA input as low as 0.5 ng (equivalent to ~ 100 cells)
  • Up to 3 donors detectable
  • Data analysis provides 95% confidence intervals and sensitivity levels.
  • DNA to Data in 12 hours

Overview

ScisGo Chimerism MD Typing Kit (cat. no. CHIM-24S-MD) is designed for use on the Illumina MiSeq Sequencing by Synthesis (SBS) platform to perform chimerism testing (engraftment analysis) after allogeneic hematopoietic cell transplantation (HCT), routinely performed as a prognostic measure of engraftment and related clinical outcomes.

Our 4-reaction Chimerism assay employs simple to perform laboratory steps and takes advantage of Next Generation Sequencing (NGS) technology to advance testing into the next generation of sensitivity and accuracy. Our assay can be adjusted for capacity and sensitivity by varying the number of reactions used and samples analyzed. Turnaround times from DNA to data are comparable to other commonly used methodologies.